Filing Flows › Pure Bioscience (PURE) › Q2 FY25
Pure Bioscience (PURE) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed Mar 17, 2025
Pure Bioscience (PURE) reported revenue of $391K for the second quarter fiscal 2025 (Q2 FY25), +20% from a year earlier and -30% from the quarter before. Operating margin was -185.4%, net loss $798K (204.1% of revenue).
Pure Bioscience, Q2 FY25: revenue $391K (+20% year over year), operating margin -185.4%, net loss $798K, operating cash flow −$544K. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $391K | -30% | +20% |
| Operating profit | −$725K | — | — |
| Net earnings | −$798K | — | — |
| Operating cash flow | −$544K | — | — |
What changed
Revenue was $391K in Q2 FY25, up 20% year over year and down 30% from the previous quarter. PURE Hard Surface was the largest line at 98% of revenue. PURE Hard Surface added $59K year over year (up 18%), 89% of the total change.
Gross margin was 58.1%, up 3.6 points from a year earlier. Operating costs exceeded revenue by $725K, an operating margin of -185.4%. Operating expenses fell 17% while revenue rose 20%. The quarter ended with a net loss of $798K, wider than the previous quarter's $689K loss.
Operating cash flow was −$544K. Non-cash charges added back $27K of share-based compensation. Working capital and other items added $227K.
Questions
What was Pure Bioscience's revenue in the second quarter fiscal 2025?
Pure Bioscience (PURE) reported revenue of $391K for the second quarter fiscal 2025 (Q2 FY25), +20% from a year earlier and -30% from the quarter before.
Was Pure Bioscience profitable in the second quarter fiscal 2025?
Operating loss was $725K (-185.4% of revenue) and net loss $798K.
Source: Pure Bioscience 10-Q on SEC EDGAR.